Algo version: 0.98b
Regeneron Pharmaceuticals is listed at the LSE Exchange
Regeneron Pharmaceuticals [0R2M.L]
LSE Sector: Healthcare Industry:Medical Pharmaceuticals

Is Regeneron Pharmaceuticals stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Regeneron Pharmaceuticals pays dividends. Last time was Thursday 1st of January 1970 where the investors holding the stock on Tuesday 15th of March 2022 were paid $0.285 per share. Over the last 1 times between 2022 and 2022, Regeneron Pharmaceuticals has paid $0.285 with an average of $0.29 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Regeneron Pharmaceuticals 10 years ago, but if you had invested on Tuesday 1st of February 2022 when the price was $607.23, you would have made a profit of $139.24 per share or 22.93%

Yes, the average daily trading liquidity for Regeneron Pharmaceuticals is $1 962 thousand. You should therefore be able to get in and out of your positions relatively fast.

Regeneron Pharmaceuticals has little of the business financed by loans. This puts the company at lower risk in periods of high inflation where borrowing costs usually go up. With a high cash flow to debt ratio of 2.14, the company's ability to pay off the debt is good. Regeneron Pharmaceuticals has a very good net profit margin of 33.61% and should have very high tolerances against inflation.

We have calculated the inflation risk for Regeneron Pharmaceuticals to be low [0 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.